Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AS210
- Development stage
- Phase 2
- Lead developer
- Vrije University Medical Center
- Modality
- Cell Therapies
- Administration
- Topical
01
Overview
AS210 is an autologous somatic cell therapy product consisting of cultured keratinocytes and fibroblasts derived from a patient's own skin biopsy. Developed by the Vrije Universiteit Medisch Centrum (VUmc), it is designed to promote the healing of chronic, hard-to-heal wounds such as (arterio-)venous leg and foot ulcers. The therapy works by providing a living tissue construct that releases essential growth factors and cytokines, stimulating the patient's own cells to migrate and proliferate, thereby accelerating re-epithelialization and dermal repair. In clinical trials, it has been compared against other cell-based products like Tiscover to evaluate its efficacy and safety in patients with chronic ulcers that have failed standard care.
- Other names
- autologous keratinocyte and fibroblast product
Beyond the preview
Go deeper on AS210.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AS210.